
PEN
Penumbra Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
234.360
Open
233.010
VWAP
232.75
Vol
304.83K
Mkt Cap
9.03B
Low
229.9425
Amount
70.95M
EV/EBITDA(TTM)
49.84
Total Shares
38.76M
EV
8.67B
EV/OCF(TTM)
48.40
P/S(TTM)
7.43
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
361.16M
+14.47%
1.125
+15.97%
341.78M
+13.53%
0.968
+13.83%
327.37M
+9.34%
0.821
+28.34%
Estimates Revision
The market is revising Upward the revenue expectations for Penumbra, Inc. (PEN) for FY2025, with the revenue forecasts being adjusted by 0.01% over the past three months. During the same period, the stock price has changed by -21.60%.
Revenue Estimates for FY2025
Revise Upward

+0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+0.09%
In Past 3 Month
Stock Price
Go Down

-21.60%
In Past 3 Month
16 Analyst Rating

37.10% Upside
Wall Street analysts forecast PEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 319.58 USD with a low forecast of 260.00 USD and a high forecast of 340.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
4 Hold
0 Sell
Strong Buy

37.10% Upside
Current: 233.100

Low
260.00
Averages
319.58
High
340.00

37.10% Upside
Current: 233.100

Low
260.00
Averages
319.58
High
340.00
Citi
Neutral
downgrade
$320 -> $285
2025-07-09
Reason
Citi
Price Target
$320 -> $285
2025-07-09
downgrade
Neutral
Reason
Citi lowered the firm's price target on Penumbra to $285 from $320 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.
Stifel
Mathew Blackman
Buy
maintain
$301 -> $318
2025-04-24
Reason
Stifel
Mathew Blackman
Price Target
$301 -> $318
2025-04-24
maintain
Buy
Reason
Stifel analyst Mathew Blackman raised the firm's price target on Penumbra to $318 from $301 and keeps a Buy rating on the shares. Q1 results were "across-the-board ahead of expectations" and the company re-affirmed or raised key guidance metrics, says the analyst, who sees Penumbra "emerging as a port in stormy waters."
BTIG
NULL -> Buy
maintain
$305 -> $320
2025-04-24
Reason
BTIG
Price Target
$305 -> $320
2025-04-24
maintain
NULL -> Buy
Reason
BTIG raised the firm's price target on Penumbra to $320 from $305 and keeps a Buy rating on the shares. The company's Q1 results topped estimates and as Penumbra moves through the remainder of FY25, comps ease notably within Thrombectomy, the analyst tells investors in a research note.
Baird
David Rescott
Outperform
maintain
$316 -> $325
2025-04-24
Reason
Baird
David Rescott
Price Target
$316 -> $325
2025-04-24
maintain
Outperform
Reason
Baird analyst David Rescott raised the firm's price target on Penumbra to $325 from $316 and keeps an Outperform rating on the shares. The firm updated its model following standout Q1 results and expectations for a THUNDERBOLT-drive acceleration.
RBC Capital
Outperform
maintain
$315 -> $330
2025-04-24
Reason
RBC Capital
Price Target
$315 -> $330
2025-04-24
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Penumbra to $330 from $315 and keeps an Outperform rating on the shares. The company delivered a Q1 beat, and maintained 2025 guidance despite China headwinds and given its recent guidance philosophy of conservatism, the analyst tells investors in a research note. Penumbra's business momentum is robust as it posted solid high-teens underlying growth in Q1 ex-China, the firm adds.
UBS
Buy
maintain
$320 -> $330
2025-04-24
Reason
UBS
Price Target
$320 -> $330
2025-04-24
maintain
Buy
Reason
UBS raised the firm's price target on Penumbra to $330 from $320 and keeps a Buy rating on the shares. Relatively limited macro exposure leaves room for potential upside, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Penumbra Inc (PEN.N) is 58.58, compared to its 5-year average forward P/E of 245.71. For a more detailed relative valuation and DCF analysis to assess Penumbra Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
245.71
Current PE
58.58
Overvalued PE
513.96
Undervalued PE
-22.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
105.14
Current EV/EBITDA
35.71
Overvalued EV/EBITDA
168.44
Undervalued EV/EBITDA
41.83
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
9.19
Current PS
6.37
Overvalued PS
11.89
Undervalued PS
6.48
Financials
Annual
Quarterly
FY2025Q1
YoY :
+16.32%
324.14M
Total Revenue
FY2025Q1
YoY :
+233.44%
40.35M
Operating Profit
FY2025Q1
YoY :
+256.51%
39.22M
Net Income after Tax
FY2025Q1
YoY :
+257.14%
1.00
EPS - Diluted
FY2025Q1
YoY :
+9.34%
35.50M
Free Cash Flow
FY2025Q1
YoY :
+2.46%
66.60
Gross Profit Margin - %
FY2025Q1
YoY :
+26.12%
12.12
FCF Margin - %
FY2025Q1
YoY :
+206.33%
12.10
Net Margin - %
FY2025Q1
YoY :
-58.28%
3.50
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
31.1M
USD
13
3-6
Months
45.1M
USD
18
6-9
Months
8.2M
USD
8
0-12
Months
12.7M
USD
10
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
77.4K
Volume
3
6-9
Months
177.6K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
43.3K
Volume
Months
6-9
5
184.3K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
31.1M
USD
13
3-6
Months
45.1M
USD
18
6-9
Months
8.2M
USD
8
0-12
Months
12.7M
USD
10
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PEN News & Events
Events Timeline
2025-06-05 (ET)
2025-06-05
09:05:18
Penumbra announces FDA approval, launch of Ruby XL System

2025-04-23 (ET)
2025-04-23
16:29:02
Penumbra backs FY25 revenue $1.34B-$1.36B, consensus $1.35B

2025-04-23
16:28:22
Penumbra reports Q1 EPS $1.00, consensus 67c

Sign Up For More Events
Sign Up For More Events
News
8.0
07-23ReutersFive years after COVID, pharma shares languish in US policy limbo
4.0
07-09BenzingaCitigroup Maintains Neutral on Penumbra, Lowers Price Target to $285
2.0
07-09NASDAQ.COMOversold Conditions For Penumbra (PEN)
Sign Up For More News
People Also Watch

PSN
Parsons Corp
76.060
USD
+0.68%

OHI
Omega Healthcare Investors Inc
39.110
USD
+0.28%

DOCS
Doximity Inc
60.770
USD
+0.20%

GL
Globe Life Inc
135.130
USD
+2.74%

AIT
Applied Industrial Technologies Inc
272.130
USD
+1.51%

EDU
New Oriental Education & Technology Group Inc
46.680
USD
+2.55%

RRC
Range Resources Corp
35.400
USD
-2.34%

SSB
SouthState Corp
98.500
USD
+0.61%

HTHT
H World Group Ltd
33.285
USD
-1.96%

LKQ
LKQ Corp
32.170
USD
+1.39%
FAQ

What is Penumbra Inc (PEN) stock price today?
The current price of PEN is 233.1 USD — it has increased 1.27 % in the last trading day.

What is Penumbra Inc (PEN)'s business?

What is the price predicton of PEN Stock?

What is Penumbra Inc (PEN)'s revenue for the last quarter?

What is Penumbra Inc (PEN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Penumbra Inc (PEN)'s fundamentals?

How many employees does Penumbra Inc (PEN). have?
